Lenalidomide

Price	$2500
Package	1KG

Product Details

Product Name: Lenalidomide	CAS No.: 191732-72-6
EC-No.: 1308068-626-2	Min. Order: 1KG
Purity: 99%	Supply Ability: 100KG
Release date: 2019/07/06

CR297

Product Name:	Lenalidomide
Synonyms:	lenalidomide;3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione;LenalidomideLenalidomide;1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline;3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione;CC-5013;Revlimi;Lenalidomide(other anti-cancers)
CAS:	191732-72-6
MF:	C13H13N3O3
MW:	259.26062
EINECS:	1308068-626-2
Product Categories:	Molecular Targeted Antineoplastic;Intermediates & Fine Chemicals;Pharmaceuticals;Amines;Heterocycles;Inhibitor;CC-5013;Inhibitors;pharmaceutical intermediate
Mol File:	191732-72-6.mol

Lenalidomide Chemical Properties

Melting point	269-271°C
storage temp.	-20°C Freezer
CAS DataBase Reference	191732-72-6(CAS DataBase Reference)

Safety Information

Risk Statements	20/21/22
Safety Statements	36/37
HazardClass	IRRITANT

MSDS Information

Lenalidomide Usage And Synthesis

Antitumor Drug	Lenalidomide is a kind of antitumor drugs that developed by American biological pharmaceutical companies. Its chemical structure is similar with thalidomide. It has many functions such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of inflammatory cytokines, and increase the secretion of peripheral blood mononuclear anti-inflammatory cytokines. Vitro tests show that lenalidomide can inhibit the hyperplasia of some cell lines such as namalwa cell. It can inhibit the growth of patients’ multiple myeloma cells and MM1S cell. In addition, lenalidomide also can inhibit the expression of oxidase-2 (COX-2), but it has no effect on COX-1. Two multicenter randomized double-blind placebo-controlled clinical studies evaluate the safety and curative effect of lenalidomide that is used for multiple myeloma. The primary efficacy end point of the studies is time to progression (TTP). The interim analysis shows that TTP of the combination group is significantly superior to dexamethasone group. Recent clinical research results show that lenalidomide not only has curative effect on treating MDS and MM, but also on treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis and systemic bone marrow fibrosis disease with marrow unripe. Lenalidomide is a new derivative of thalidomide. But its teratogenic toxicity has not found. Its effectiveness is 100 times stronger than thalidomide. According to the result of three clinical trials, lenalidomide is the most effective drug in the treatment of multiple myeloma. More than half of patients can prolong survival time to more than 3 years after taking the drug. In addition, it is also the only effective drugs to treat myelodysplastic syndrome (MDS). Clinical results find that 64% of the patients with MDS need not use blood transfusion after treated by lenalidomide. In December 2005, the US Food and Drug Administration (FDA) approved lenalidomide to be used in the treatment of myelodysplastic syndrome (MDS). In March 2006, the FDA approved lenalidomide that was produced by American Celgene Biological Pharmaceutical Companies to be used in the treatment of multiple myeloma (MM). On September 23, 2011, the European Medicines Agency (EMA) released information that they have confirmed that the benefits of lenalidomide(trade name: Revlimid) to be used in the treatment of patients group that was approved outweighed the risks. Meanwhile they warned the doctor the risk of the drug to cause new cancer cases. Lenalidomide has been used with dexamethasone to treat adult patients with multiple myeloma that has received at least one treatment. Three new studies show that the incidence of new cancer will be increased in the patients with newly diagnosed multiple myeloma treated by lenalidomide and other combined treatment increased incidence of cancer. The above information is edited by the Chemicalbook Geqian.
Chemical Properties	Yellow Solid
Uses	Immunomodulatory drug; analog of Thalidomide.
Uses	Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.
Uses	Lovastatin content <1% 98%
Uses	A Thalidomide analog known to have immunomodulatory properties
Definition	ChEBI: A dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha.

Company Profile Introduction

Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals. Mainly deals in the sales of: Pharmaceutical intermediates OLED intermediates： Pharmaceutical intermediates; OLED intermediates;

Recommended supplier

Product name	Price		Suppliers	Update time
Lenalidomide	$8.00/1KG	VIP1Y	Henan Fengda Chemical Co., Ltd	2024-03-28
Lenalidomide	$110.00/1kilogram		Henan Tengmao Chemical Technology Co. LTD	2024-02-03
Lenalidomide	$50.00/1kg	VIP1Y	Zibo Hangyu Biotechnology Development Co., Ltd	2023-11-20
Lenalidomide	$40.00/1kg	VIP4Y	Hebei Yanxi Chemical Co., Ltd.	2023-09-07
Lenalidomide	$0.00/1kg	VIP1Y	SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.	2023-09-07
Lenalidomide	$100.00/1kg	VIP1Y	Henan Bao Enluo International TradeCo.，LTD	2023-08-10
Lenalidomide	$0.00/1g	VIP1Y	Hangzhou ICH Biofarm Co., Ltd	2023-06-12
Lenalidomide	$200.00/10g		Hebei Best Biological Technology Co., Ltd	2022-11-09
Lenalidomide	$0.00/1kg		HangZhou RunYan Pharma Technology Co.,LTD.	2022-11-08
Lenalidomide	$0.00/1KG	VIP2Y	Wuhan Senwayer Century Chemical Co.,Ltd	2022-11-07

Product Details

Company Profile Introduction

You may like

Recommended supplier

career henan chemical co